These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
90 related articles for article (PubMed ID: 26352099)
1. Heterotopic Mucosal Grafting Enables the Delivery of Therapeutic Neuropeptides Across the Blood Brain Barrier. Bleier BS; Kohman RE; Guerra K; Nocera AL; Ramanlal S; Kocharyan AH; Curry WT; Han X Neurosurgery; 2016 Mar; 78(3):448-57; discussion 457. PubMed ID: 26352099 [TBL] [Abstract][Full Text] [Related]
2. Neurotrophic and neuroprotective efficacy of intranasal GDNF in a rat model of Parkinson's disease. Migliore MM; Ortiz R; Dye S; Campbell RB; Amiji MM; Waszczak BL Neuroscience; 2014 Aug; 274():11-23. PubMed ID: 24845869 [TBL] [Abstract][Full Text] [Related]
3. Continuous exposure to glial cell line-derived neurotrophic factor to mature dopaminergic transplants impairs the graft's ability to improve spontaneous motor behavior in parkinsonian rats. Winkler C; Georgievska B; Carlsson T; Lacar B; Kirik D Neuroscience; 2006 Aug; 141(1):521-31. PubMed ID: 16697115 [TBL] [Abstract][Full Text] [Related]
4. Intravenous treatment of experimental Parkinson's disease in the mouse with an IgG-GDNF fusion protein that penetrates the blood-brain barrier. Fu A; Zhou QH; Hui EK; Lu JZ; Boado RJ; Pardridge WM Brain Res; 2010 Sep; 1352():208-13. PubMed ID: 20599807 [TBL] [Abstract][Full Text] [Related]
5. Early transplantation of an encapsulated glial cell line-derived neurotrophic factor-producing cell demonstrating strong neuroprotective effects in a rat model of Parkinson disease. Yasuhara T; Shingo T; Muraoka K; Kobayashi K; Takeuchi A; Yano A; Wenji Y; Kameda M; Matsui T; Miyoshi Y; Date I J Neurosurg; 2005 Jan; 102(1):80-9. PubMed ID: 15658100 [TBL] [Abstract][Full Text] [Related]
6. GDNF-secreting mesenchymal stem cells provide localized neuroprotection in an inflammation-driven rat model of Parkinson's disease. Hoban DB; Howard L; Dowd E Neuroscience; 2015 Sep; 303():402-11. PubMed ID: 26166730 [TBL] [Abstract][Full Text] [Related]
7. Dopamine D1 and D2 receptor-mediated acute and long-lasting behavioral effects of glial cell line-derived neurotrophic factor administered into the striatum. Kobayashi S; Ogren SO; Hoffer BJ; Olson L Exp Neurol; 1998 Dec; 154(2):302-14. PubMed ID: 9878169 [TBL] [Abstract][Full Text] [Related]
8. Intracerebral administration of ultrasound-induced dissolution of lipid-coated GDNF microbubbles provides neuroprotection in a rat model of Parkinson's disease. Wang X; Cui G; Yang X; Zhang Z; Shi H; Zu J; Hua F; Shen X Brain Res Bull; 2014 Apr; 103():60-5. PubMed ID: 24583079 [TBL] [Abstract][Full Text] [Related]
9. Evidence for an Additive Neurorestorative Effect of Simultaneously Administered CDNF and GDNF in Hemiparkinsonian Rats: Implications for Different Mechanism of Action. Voutilainen MH; De Lorenzo F; Stepanova P; Bäck S; Yu LY; Lindholm P; Pörsti E; Saarma M; Männistö PT; Tuominen RK eNeuro; 2017; 4(1):. PubMed ID: 28303260 [TBL] [Abstract][Full Text] [Related]
10. Differential effects of glial cell line-derived neurotrophic factor (GDNF) in the striatum and substantia nigra of the aged Parkinsonian rat. Connor B; Kozlowski DA; Schallert T; Tillerson JL; Davidson BL; Bohn MC Gene Ther; 1999 Dec; 6(12):1936-51. PubMed ID: 10637445 [TBL] [Abstract][Full Text] [Related]
11. Ex vivo gene delivery of GDNF using primary astrocytes transduced with a lentiviral vector provides neuroprotection in a rat model of Parkinson's disease. Ericson C; Georgievska B; Lundberg C Eur J Neurosci; 2005 Dec; 22(11):2755-64. PubMed ID: 16324109 [TBL] [Abstract][Full Text] [Related]
12. Grafting of encapsulated genetically modified cells secreting GDNF into the striatum of parkinsonian model rats. Date I; Shingo T; Yoshida H; Fujiwara K; Kobayashi K; Takeuchi A; Ohmoto T Cell Transplant; 2001; 10(4-5):397-401. PubMed ID: 11549061 [TBL] [Abstract][Full Text] [Related]
14. Intranasal Administration of GDNF Protects Against Neural Apoptosis in a Rat Model of Parkinson's Disease Through PI3K/Akt/GSK3β Pathway. Yue P; Gao L; Wang X; Ding X; Teng J Neurochem Res; 2017 May; 42(5):1366-1374. PubMed ID: 28247332 [TBL] [Abstract][Full Text] [Related]
16. Lentiviral vectors as a gene delivery system in the mouse midbrain: cellular and behavioral improvements in a 6-OHDA model of Parkinson's disease using GDNF. Bensadoun JC; Déglon N; Tseng JL; Ridet JL; Zurn AD; Aebischer P Exp Neurol; 2000 Jul; 164(1):15-24. PubMed ID: 10877911 [TBL] [Abstract][Full Text] [Related]
17. Telmisartan attenuates MPTP induced dopaminergic degeneration and motor dysfunction through regulation of α-synuclein and neurotrophic factors (BDNF and GDNF) expression in C57BL/6J mice. Sathiya S; Ranju V; Kalaivani P; Priya RJ; Sumathy H; Sunil AG; Babu CS Neuropharmacology; 2013 Oct; 73():98-110. PubMed ID: 23747572 [TBL] [Abstract][Full Text] [Related]
18. Comparison of the capability of GDNF, BDNF, or both, to protect nigrostriatal neurons in a rat model of Parkinson's disease. Sun M; Kong L; Wang X; Lu XG; Gao Q; Geller AI Brain Res; 2005 Aug; 1052(2):119-29. PubMed ID: 16018990 [TBL] [Abstract][Full Text] [Related]
19. Intracerebroventricular glial cell line-derived neurotrophic factor improves motor function and supports nigrostriatal dopamine neurons in bilaterally 6-hydroxydopamine lesioned rats. Bowenkamp KE; Lapchak PA; Hoffer BJ; Miller PJ; Bickford PC Exp Neurol; 1997 May; 145(1):104-17. PubMed ID: 9184114 [TBL] [Abstract][Full Text] [Related]
20. Long-term survival of encapsulated GDNF secreting cells implanted within the striatum of parkinsonized rats. Grandoso L; Ponce S; Manuel I; Arrúe A; Ruiz-Ortega JA; Ulibarri I; Orive G; Hernández RM; Rodríguez A; Rodríguez-Puertas R; Zumárraga M; Linazasoro G; Pedraz JL; Ugedo L Int J Pharm; 2007 Oct; 343(1-2):69-78. PubMed ID: 17583454 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]